Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 23, 2023 - Issue 1
Submit an article Journal homepage
104
Views
1
CrossRef citations to date
0
Altmetric
Original Research

The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology

Aneta Melaa Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, PolandCorrespondence[email protected]
View further author information
,
Elżbieta Rdzaneka Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CePT), Medical University of Warsaw, Warsaw, PolandView further author information
,
Andrzej Tysarowskib Department of Pathology and Laboratory Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland;c Department of Molecular and Translational Oncology, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PolandView further author information
,
Magdalena Sakowiczd Department of Health Services Billing, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, PolandView further author information
,
Janusz Jaroszyńskie Department of Administrative Procedure, Faculty of Law and Administration, Maria Curie-Skłodowska University of Lublin, Lublin, PolandView further author information
,
Marzena Furtak-Niczyporukf Department of Public Health, Faculty of Medicine, Medical University of Lublin, Lublin, PolandView further author information
,
Grzegorz Żurekg Department of Biostructure, Wrocław University of Health and Sport Sciences, Wrocław, PolandView further author information
,
Łukasz A. Poniatowskih Department of Neurosurgery, Otto-von-Guericke University Magdeburg, Magdeburg, GermanyView further author information
&
Beata Jagielskai President of the Polish Alliance for Personalized Medicine Association; Rafal‚ Masztak Grochów Hospital Independent Public Healthcare Centre, Warsaw, PolandView further author information
 show all
Pages 43-54 | Received 22 Mar 2022, Accepted 21 Oct 2022, Published online: 27 Nov 2022

References

  • A: WHO report on cancer: setting priorities, investing wisely and providing care for all. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
  • B Mathur S, Sutton J. Personalized medicine could transform healthcare. Biomed Rep. 2017;7(1):3–5.
  • Ginsburg C:, Geoffrey S, Kathryn AP. Precision medicine: from science to value. Health Aff (Millwood). 2018;37(5):694–701.
  • Malone D:, Eoghan R, Sabatini PJB, et al. Molecular profiling for precision cancer therapies. Genome Med. 2020 Jan 14;12(1):8.
  • FEDORYSZAK-RODZ M, Swiderek M, Tyszka N. The use of valuations of healthcare services in other countries (basic benefits basket) in the tariffing process. Zdrowie Publiczne i Zarządzanie. 2019;17(4):241–258.
  • Ordinance No. 184/2019/DSOZ of the president of the national health fund on defining the conditions for concluding and implementing contracts such as: hospital treatment and hospital treatment - highly specialized services.
  • Ricci AD, Rizzo A, Rojas Llimpe FL, et al. HER2-Directed treatments in advanced gastric carcinoma: another paradigm shift? Cancers (Basel). 2021 Apr 1;13(7):1664. PMID: 33916206; PMCID: PMC8036476.
  • Rizzo A, Ricci AD. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials? Expert Opin Investig Drugs. 2022Apr;31(4):415–423. Epub 2021 Aug 30. PMID: 34429006.
  • Jagielska B, Sakowicz M, Twarowski A, et al. Raport z III cyklu warsztatów rozliczeniowych “Praktyczne aspekty zarządzania przychodami z NFZ i ich wpływ na kondycję finansową ośrodka. Polska Koalicja Medycyny Personalizowanej, INNOWO. 2020.
  • Chorostowska-Wynimko J, Didkowska J, Jagielska B, et al. Wpływ zmiany finansowania diagnostycznych badań genetycznych na dostępność do terapii innowacyjnych. Warszawa: Polska Koalicja Medycyny Personalizowanej, Instytut Innowacji i Odpowiedzialnego Rozwoju, 2020.
  • Adamek M, Chorostowska-Wynimko J, Głogowski M, et al. Wyzwania diagnostyki patomorfologicznej i molekularnej oraz leczenia raka płuca. Polska Koalicja Medycyny Personalizowanej, INNOWO. 2020.
  • Macuda M. Diagnosis-related group prospective payment system in Poland – costs versus tariffs: the case of inguinal hernia. Nauki o finansach. Prace Naukowe Uniwersytetu Ekonomicznego we Wrocławiu. 2018;23(3):102–110.
  • Sąsiadek M, Witt M, Misiak B. Zastosowanie osiągnięć medycyny personalizowanej w praktyce klinicznej, str. 19. Praca zbiorowa pod redakcją dr hab. Adama Fronczaka
  • Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008;8(6):473–480.
  • Fronczak A. ”Medycyna personalizowana.” Mity, fakty, rekomendacje. Plexus sc, Łódź. . 2016.
  • Arteaga CL, Sliwkowski MX, Osborne CK, et al. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol. 2011Nov29;9(1):16–32. PMID: 22124364.
  • Russo A, Franchina T, Ricciardi GR, et al. A decade of EGFR inhibition in EGFR-mutated non-small cell lung cancer (NSCLC): old successes and future perspectives. Oncotarget. 2015Sep29;6(29):26814–26825. PMID: 26308162; PMCID: PMC4694955.
  • Spagnolo F, Ghiorzo P, Orgiano L, et al. BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. Onco Targets Ther. 2015 Jan 16;8:157–168. PMID: 25653539; PMCID: PMC4303458.
  • Kluska A, Balabas A, Paziewska A, et al. New recurrent BRCA1/2 mutations in Polish patients with familial breast/ovarian cancer detected by next generation sequencing. BMC Med Genomics. 2015May7;8(1):19. PMID: 25948282; PMCID: PMC4429836.
  • Friedman AA, Letai A, Fisher DE, et al. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015Dec;1512:747–756. Epub 2015 Nov 5. PMID: 26536825; PMCID: PMC4970460
  • Zhang Y, Wu S, Zhuang X, et al. Identification of an activating mutation in the extracellular domain of HER2 conferring resistance to pertuzumab. Onco Targets Ther. 2019 Dec 30;12:11597–11608. PMID: 31920346; PMCID: PMC6941612.
  • Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646–674. PMID: 21376230.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.